Home Biosimilar Antibodies Immunology & Inflammation CD markers Anti-Siglec-15 / CD33L3 (NC318)
For research use only. Not for use in humans.

Anti-Siglec-15 / CD33L3 (NC318)

Synonyms: NC318

Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.

Anti-Siglec-15 / CD33L3 (NC318)

Quality Control

Batch: Purity: 99% Protein concentration: 10.762mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.
References

Product Details

Molecular Weight 146.98
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04699123 ACTIVE_NOT_RECRUITING Drug: NC318 800 mg|Drug: NC318 400 mg|Drug: Pembrolizumab Advanced Non-small Cell Lung Cancer Yale University 2021-02-04 PHASE2
NCT03665285 COMPLETED Drug: NC318 Advanced or Metastatic Solid Tumors; Lung Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma; Endometrial Cancer; Melanoma; CRC; Urothelial Carcinoma; Cholangiocarcinoma NextCure, Inc. 2018-10-01 PHASE1; PHASE2
NCT04430933 WITHDRAWN Drug: NC318|Drug: Pemetrexed/Carboplatin|Drug: Nab paclitaxe Advanced or Metastatic Solid Tumors; Non-Small Cell Lung Cancer NextCure, Inc. 2021-12-06 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.